Lilly Prasugrel Beats Plavix In TRITON, But Bleeding Data Raise Questions
Executive Summary
Eli Lilly released powerful efficacy results from an eagerly anticipated Phase III head-to-head trial of its experimental antiplatelet agent prasugrel, which has the potential to take market share from Bristol-Myers Squibb's blockbuster Plavix (clopidogrel)
You may also be interested in...
Prasugrel Could Avoid More Restrictive REMS Options, Lilly Hints
Should a risk management and evaluation strategy accompany approval of Lilly's anti-platelet drug prasugrel, the product may escape the most burdensome REMS options, Lilly hinted during its July 24 earning call
Prasugrel Could Avoid More Restrictive REMS Options, Lilly Hints
Should a risk management and evaluation strategy accompany approval of Lilly's anti-platelet drug prasugrel, the product may escape the most burdensome REMS options, Lilly hinted during its July 24 earning call
Lilly/Daiichi Submit Prasugrel; Showdown With Plavix Timed For Second Half
Lilly and Daiichi Sankyo plan to launch the antiplatelet drug prasugrel immediately after it is approved, supported by an extensive sales force including representatives from both companies